Draft:Nutcracker Therapeutics
Biotech company developing mRNA drugs
 | This article, Draft:Nutcracker Therapeutics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
| This article, Draft:Nutcracker Therapeutics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
| This article, Draft:Nutcracker Therapeutics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
| This article, Draft:Nutcracker Therapeutics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
| This article, Draft:Nutcracker Therapeutics, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
Comment: To establish notability it needs multiple reliable independent sources with in-depth coverage of the subject not just passing mentions or interviews, sayings of the company, or connected person of the subject. GrabUp - Talk 17:12, 16 May 2024 (UTC)
- Comment: Appears to not be an improvement. Toadette (Happy holiday!) 06:05, 9 December 2023 (UTC)
- Comment: Press releases, patents and article by staffers are not independent. Stuartyeates (talk) 19:02, 1 December 2023 (UTC)
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[2]. As of 2023, NTX-250 is in the preclinical stage of development.
References
- ^ Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478. PMID 35945442.
- ^ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.